First, OCF and its science advisory board are not advocates for the Oraldna HPV test. It is not of any value as a testing/screening mechanism for the public, but definitely makes money for the dentists that they are selling it to. I can explain this at a later time if someone wants to know why, but I don't have the time tonight.

There are peer reviewed published studies that clearly show a significant survival advantage for HPV+ oral cancers which occur mostly in the tonsil and the base of the tongue, and the walls of the oropharynx. The disease from this cause responds better to conventional radiation and chemo than tobacco origin cancers.

The HPV page in the OCF web site has numerous PDF's of the original scientific articles related to HPV and several related to the implication in survival of HPV+ status. One is located here, but there are more

http://www.oralcancerfoundation.org/HPV/pdf/NEJM_Gillison.pdf

And a quote from this particular published article in the NEJM, which has some of the strictest peer review processes out there.

"The extent to which the superior survival for a patient with HPV-positive oropharyngeal squamous- cell carcinoma depends on the administered therapy is unclear. Published data indicate that tumor HPV status is a strong and consistent determinant of superior survival, regardless of treatment strategy (e.g., surgery, radiation therapy, concurrent chemoradiation therapy [in this study], or induction chemotherapy plus concurrent chemo-radiation therapy, with 5-year survival rates among patients with HPV positive tumors of approximately 75 to 80%, versus 45 to 50% among patients with HPV negative tumors."